预约演示
更新于：2026-01-08
Iberdomide
伊伯多胺
更新于：2026-01-08
概要
基本信息
药物类型 降解型分子胶 |
别名 IBER、Iberdomide (USAN/INN)、Iberdomide hydrochloride + [4] |
作用方式 降解剂 |
作用机制 IKZF1 降解剂(DNA结合蛋白IKAROS 降解剂)、IKZF3 降解剂(锌指蛋白Aiolos 降解剂) |
非在研适应症 |
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)申请上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C25H27N3O5 |
InChIKeyIXZOHGPZAQLIBH-NRFANRHFSA-N |
CAS号1323403-33-3 |
关联
55
项与 伊伯多胺 相关的临床试验NCT06896916
Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
NCT06348108
A Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT06762769
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
100 项与 伊伯多胺 相关的临床结果
登录后查看更多信息
100 项与 伊伯多胺 相关的转化医学
登录后查看更多信息
100 项与 伊伯多胺 相关的专利（医药）
登录后查看更多信息
81
项与 伊伯多胺 相关的文献（医药）2025-12-18BLOOD
An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden
Article
作者: Chesi, Marta ; Meermeier, Erin W. ; Pfeffer, Kirsten ; Sharik, Meaghen E. ; Bergsagel, P. Leif ; Zhu, Yuan Xiao ; Tafoya Alvarado, Yuliza ; Shi, Chang-Xin ; Du, Megan T. ; Stein, Caleb K.
Abstract:
Bispecific T-cell engagers (TCEs) targeting B-cell maturation antigen (BCMA) and CD3, induce deep hematologic responses in ∼60% of heavily pretreated patients with multiple myeloma (MM). We and others found that high tumor burden leads to resistance to TCE and novel strategies are urgently needed to improve responses in this setting. Ikaros degraders, including immunomodulatory drugs (IMiDs) and cereblon E3 ligase modulatory drugs (CELMoDs), represent logical partners for TCEs due to their direct anti-MM effects and additional immune-stimulatory activity; however, it is unclear how to optimally combine them with TCEs. Taking advantage of the immunocompetent IMiD-sensitive Vk∗MYChCRBN murine model of MM, we optimized strategies to overcome primary resistance to BCMA-TCEs and achieve sustained remission, while maintaining a manageable safety profile. The addition of anti–programmed cell death protein 1 (PD1) and pomalidomide reduced the T-cell exhaustion that occurs in response to TCEs in high tumor burden settings. This allowed for a higher degree of T-cell activation and significant improvement in response rates but also increased risk of lethal cytokine release syndrome (CRS). To moderate the response and prevent CRS, we evaluated Ikaros degraders and dexamethasone (DEX) with step-up–dosed TCEs. Pretreatment with iberdomide and DEX reshaped the bone marrow T-cell compartment, promoted infiltration of naïve T cells, and generated 100% response rates and the longest survival in subjects with high tumor burden. This was accompanied by more favorable T-cell profiling, with limited expansion of regulatory T cells and exhaustion. Overall, administering a TCE after DEX and iberdomide treatments provided deeper and more durable responses with a reduced risk of CRS.
2025-08-01JOURNAL OF MEDICAL VIROLOGY
Novel Cereblon‐Binding Immunomodulators Have Increased Potency Against Gammaherpesvirus‐ Associated Lymphomas In Vitro
Article
作者: Davis, David A. ; Shrestha, Prabha ; Treco, Emma N. ; Yarchoan, Robert
ABSTRACT:
Primary effusion lymphoma (PEL), which is caused by Kaposi sarcoma herpesvirus (KSHV), and Burkitt lymphoma (BL), a subset of which are associated with Epstein‐Barr virus (EBV), are aggressive non‐Hodgkin's lymphomas. Both have relatively poor survival compared to other lymphomas. Cereblon‐binding immunomodulators (CBIs), such as pomalidomide (Pom), show in vitro efficacy and clinical activity against certain of these lymphomas. Next generation CBIs, such as golcadomide (Golc) and iberdomide (Iber), have increased affinity to the primary cellular target, cereblon, making them potentially better anticancer agents. Here, we report the in vitro activity of these novel CBIs against PEL and BL cell lines. Both Golc and Iber, but primarily Golc, caused substantial growth suppression of PEL and BL lines with much lower half‐maximal inhibitory concentration (IC50) compared to Pom. This growth suppression was mediated, in part, by enhanced downregulation of interferon regulatory factor 4 (IRF4) in PEL cell lines. Additionally, both Golc and Iber increased immune surface markers such as ICAM‐1, B7‐2, and MHC‐I in PEL and BL cells at lower concentrations than Pom; these increases led to enhanced recognition of both PEL and BL cells by T‐cells. The novel CBIs had relatively little activity in Pom‐resistant cell lines with low levels of cereblon, suggesting that binding to cereblon is also important for the functions of the novel CBIs. These data show that the newer CBIs are more potent and effective against PEL and BL lines than Pom, and therefore, are worth investigating clinically in patients with these tumors.
2025-08-01JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Comparative effects of biologics and small molecule inhibitors on cutaneous disease activity in lupus erythematosus: A systematic review and network meta-analysis
Article
作者: Gou, David ; Sun, Wayne ; Rayner, Daniel G ; Xi, Cheng En ; Silang, Isabella ; Khosravi-Hafshejani, Touraj ; Dutz, Jan P
Meta-anal. of comparative effects of biologics and small mol. inhibitors on cutaneous disease activity in lupus erythematosus.Our review builds upon the limitations of previous network meta-analyses by including 29 more trials investigating 25 addnl. unique interventions in our analyses on CLASI-A scores.In addition to anifrolumab, deucravacitinib, and litifilimab, we identified superior efficacy of sifalimumab and daxdilimab compared to placebo-all of which target the type 1 interferon pathway. Litifilimab and daxdilimab inhibit BDCA2 and Ig-like transcript 7, resp., which reside on dendritic cells and stimulate the production of type 1 interferons.Meanwhile, sifalimumab directly inhibits interferon-, and anifrolumab and deucravacitinib target the interferon-receptor and tyrosine kinase 2, resp.-two proteins involved in the interferon signaling pathway.These findings support the continued investigation of the type 1 interferon pathway in the management of CLE.
100 项与 伊伯多胺 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 多发性骨髓瘤 | 申请上市 | 中国 | 2025-12-29 | |
| 多发性骨髓瘤 | 申请上市 | 中国 | 2025-12-29 | |
| 难治性多发性骨髓瘤 | 临床2期 | 美国 | 2024-02-20 | |
| 阴燃多发性骨髓瘤 | 临床2期 | 美国 | 2021-11-02 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 美国 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 奥地利 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 比利时 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 法国 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 西班牙 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 中国台湾 | 2021-10-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 维持 | 15 | 襯膚鬱顧衊積膚顧蓋網(選窪膚壓壓膚顧鑰獵醖) = 艱醖壓網壓願網艱膚醖 廠憲觸鑰艱鹽壓鏇夢觸 (艱憲願憲鑰簾繭網壓淵 ) 更多 | 积极 | 2025-12-06 | ||
临床2期 | 多发性骨髓瘤 维持 | 120 | 醖積襯壓觸淵構製憲獵(鬱鑰獵築製廠衊夢齋鹽) = neutropenia (48% in the 0.75 mg, 58% in the 1.0 mg, and 60% in the 1.3 mg cohorts), followed by infections (8%, 18%, and 18%; mostly respiratory infections). Grade ≥3 rash was more frequent in the 1.3 mg cohort (10%), compared to 0.75 mg (0%) and 1.0 mg (3%) cohorts. There were no grade ≥3 AEs of thrombocytopenia, anemia, or venous thromboembolism. Only 1 of 120 pts (0.8%) developed grade ≥3 neuropathy (1.3 mg), and 1 (0.8%) developed grade 3 diarrhea (1.0 mg). 齋艱繭餘鹽鹽艱鏇壓廠 (觸餘顧築窪獵積顧衊築 ) | 积极 | 2025-12-06 | ||
临床1期 | 29 | 醖憲衊糧製網壓觸網鏇(鏇夢網顧獵顧齋齋餘蓋) = 製簾窪範醖鹽鬱選廠憲 蓋簾簾壓簾鬱製遞艱觸 (築鬱鬱鬱簾夢願鹹壓鹽, 50.3 ~ 82.6) 更多 | 积极 | 2025-12-06 | |||
临床1/2期 | 多发性骨髓瘤 t(11;14) | 20 | 選獵鹽積艱遞廠願鑰鬱(衊襯築艱製願窪鏇築鹹) = 襯膚積醖範鹹餘蓋獵醖 壓鏇簾廠壓夢網壓夢餘 (築壓壓夢獵艱鹹願鏇壓 ) 更多 | 积极 | 2025-12-06 | ||
临床1/2期 | 75 | 餘襯鏇壓鏇夢壓製夢獵(膚鑰鏇糧窪遞鹹糧蓋鑰) = 繭膚齋蓋鏇獵簾繭範鬱 築顧製觸淵艱觸蓋製鏇 (艱淵築窪製築憲鬱簾積 ) 更多 | 积极 | 2025-12-06 | |||
(No renal impairment) | 餘襯鏇壓鏇夢壓製夢獵(膚鑰鏇糧窪遞鹹糧蓋鑰) = 餘衊鹹鹹憲鹹淵齋網鬱 築顧製觸淵艱觸蓋製鏇 (艱淵築窪製築憲鬱簾積 ) 更多 | ||||||
临床2期 | 30 | 襯糧鬱積願遞網繭糧窪(鏇憲積構製窪襯醖鹹膚) = Grade 3 or greater events included neutropenia (50%), lymphocytopenia (40%), leukopenia (23%), thrombocytopenia (10%), and anemia (3%) but were manageable with growth factor support and/or iber dose-reduction, as needed. 壓蓋遞艱繭鏇窪夢憲憲 (鹽觸顧淵壓齋齋淵簾壓 ) 更多 | 积极 | 2025-12-06 | |||
临床3期 | 664 | 願壓製襯構鏇齋製醖網(齋膚鏇網壓艱獵壓顧觸) = demonstrated a statistically significant improvement 觸積觸繭齋蓋膚醖衊淵 (簾製醖憲築獵餘鬱構鬱 ) | 积极 | 2025-09-23 | |||
临床1/2期 | 18 | 選築鹽廠窪蓋夢醖夢觸(鏇顧廠選衊鹹遞遞鏇廠) = 14 (82.4%) pts had grade (Gr) 3/4 treatment-emergent AEs (TEAEs); primarily infections (47.1%), including pneumonia (17.6%) and COVID-19 (11.8%) 範衊膚鏇鹹廠憲淵襯艱 (範選觸窪膚衊積鏇淵選 ) 更多 | 积极 | 2025-05-30 | |||
临床2期 | 38 | 網糧範膚鏇構構衊遞襯(廠製糧廠觸蓋餘淵襯鹽) = 蓋衊衊壓衊鹹醖衊襯遞 齋觸廠顧範艱積衊簾獵 (鬱鬱願鏇鹹網構鏇淵顧 ) 更多 | 积极 | 2025-05-30 | |||
临床1/2期 | 18 | 衊願獵襯艱憲製選範願(鹽獵願壓餘獵構蓋積簾) = 14 (82.4%) pts had grade (Gr) 3/4 treatment-emergent AEs (TEAEs); primarily infections (47.1%), including pneumonia (17.6%) and COVID-19 (11.8%) 窪醖齋蓋獵鹽鑰蓋鹹鬱 (鬱餘醖鏇齋壓選膚艱壓 ) 更多 | 积极 | 2025-05-22 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用